Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies

Daisuke Satoh¹, Satoru Iwado², Satoshi Abe¹, Kanako Kazuki¹, Shinobu Wakuri³, Mitsuo Oshimura¹, Yasuhiro Kazuki¹,²*

¹ Chromosome Engineering Research Center, Tottori University, Tottori, Japan, ² Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Tottori, Japan, ³ Food and Drug Safety Center, Tokyo, Japan

* kazuki@grape.med.tottori-u.ac.jp

Abstract

The utility of HepG2 cells to assess drug metabolism and toxicity induced by chemical compounds is hampered by their low cytochrome P450 (CYP) activities. To overcome this limitation, we established HepG2 cell lines expressing major CYP enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and CYP oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. Transchromosomic HepG2 (TC-HepG2) cells expressing four CYPs and POR were used to determine time- and concentration-dependent inhibition and toxicity of several compounds by luminescence detection of CYP-specific substrates and cell viability assays. Gene expression levels of all four CYPs and POR, as well as the CYP activities, were higher in TC-HepG2 clones than in parental HepG2 cells. Additionally, the activity levels of all CYPs were reduced in a concentration-dependent manner by specific CYP inhibitors. Furthermore, preincubation of TC-HepG2 cells with CYP inhibitors known as time-dependent inhibitors (TDI) prior to the addition of CYP-specific substrates determined that CYP inhibition was enhanced in the TDI group than in the non-TDI group. Finally, the IC₅₀ of bioactivable compound aflatoxin B₁ was lower in TC-HepG2 cells than in HepG2 cells. In conclusion, the TC-HepG2 cells characterized in the current study are a highly versatile model to evaluate drug-drug interactions and hepatotoxicity in initial screening of candidate drug compounds, which require a high degree of processing capacity and reliability.

Introduction

Primary human hepatocytes are recommended for use in studies to predict hepatic drug metabolism and hepatotoxicity of pharmaceutical candidate compounds [1, 2]. However, primary human hepatocytes are not only expensive and ethically problematic but also are
challenging to conduct long-term assays due to their short lifespan and differences between lots; therefore, establishing specific evaluation criteria for candidate compounds remains challenging [3, 4]. These issues highlight the need for alternative human liver derived cell lines that can be used for general pharmacokinetics and hepatotoxicity evaluation studies [5]. Currently available alternative in vitro models utilizing a human liver cancer cell line HepG2 is used to provide supplementary data to support findings obtained from human hepatocytes [6, 7]. However, the expression levels of drug-metabolizing enzymes are significantly lower in the cell line than in primary human hepatocytes in vitro [8–13]. Due to these concerns, HepG2 cell lines over expressing cytochrome P450 (CYP)3A4 and related enzymes were developed [14–19].

Gene transduction can be achieved by two major methods. Transient transfection utilizes a plasmid vector [16, 17] or an adenoviral vector [14] to introduce target gene to the cell. The major advantage of this method is its ease of use in in vitro studies; however, inability to accurately control the number of copies introduced into each cell, which leads to wide variations of experimental data, is a major caveat. As an alternative, stable gene expression is achieved by insertion of the gene of interest into host chromosome using retroviral [9, 11, 15, 19] or Piggy-Bac vectors [18]. However, this approach leads to the destruction of host genomes. Furthermore, long-term culturing causes epigenetic silencing of host chromosomes, again leading to wide variations in the level of gene expression. Thus, cell-based systems reported by one research group via conventional gene transduction methods may not be reproducible by other groups.

We developed mammalian-derived artificial chromosomes [20, 21], which were derived from a native mouse chromosome (designated as MAC). MAC harbors no endogenous genes and contain loxP site for gene loading and green fluorescent protein (GFP) for monitoring its presence [22, 23]. The prominent advantage of MAC as gene delivery vector is no limitation of DNA insert size, which allows the introduction of all required genes. The mitotic stability of the MAC vectors with fixed copy number of gene permits to reduce clonal variation of the gene expression levels. Semipermanent retention of gene/s of interest in host cells allows for the construction of sustainable models. In addition, because MAC vectors are independently maintained without disruption of host chromosomes, gene transduction can proceed without disrupting the host functions. Thus, the aim of this study was to establish a novel HepG2-based cell line that stably expressed multiple pharmacokinetic-related genes lacking in parental HepG2 cells by using MAC vectors carrying four kinds of CYPs and POR genes to evaluate hepatic drug metabolism and hepatotoxicity.

Materials and methods

Chemicals

Erythromycin, clarithromycin, roxithromycin, diltiazem, ritonavir, ketoconazole, fluconazole, cimetidine, ticlopidine, omeprazole, fluvoxamine, paroxetine, fluoxetine, quinidine, aflatoxin B1, and sterigmatocystin were obtained from Wako, Japan. Gestodene and mifepristone were obtained from Tokyo Chemical Industry, Japan. G418 was obtained from Funakoshi, Japan. Ethinylestradiol, rifampicin, tienilic acid, terbinafine, hypoxanthine, aminopterin, and thymidine (HAT) and 4,6-diamidino-2-phenylindole (DAPI) were obtained from Sigma Aldrich, USA. All other chemicals were of the highest grade commercially available.

Construction of the 4CYPs-POR gene-loading PAC vector

First, we used artificial gene synthesis to develop a gene-loading PAC vector containing all four CYPs and POR (Invitrogen). A gene modification method using a P1-derived artificial
chromosome (PAC) vector was performed, as described in our previous report [24] and detailed in S1A Fig. cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) [25] and CYP oxidoreductase (POR) [26] were obtained as artificial synthetic genes (Invitrogen). Sequence data for all cDNAs were obtained from the UCSC Genome Browser (https://genome.ucsc.edu/). Construction of the basic framework was initiated by introduction of the cDNAs downstream of the forced expression promoter CAG. Next, insulators (HS4) containing a sequence to stabilize gene expression were ligated to flank the genes. The CAG-CYP and CAG-POR plasmids were digested with SalI and AvrII and inserted to the SalI/AvrII site of the HS4-carrying plasmid for the construction of four kinds of HS4-CAG-CYP and HS4-CAG-POR plasmids. Next, the HS4-CAG-CYP2C9 plasmid was digested with NheI/Ascl site and ligated with the HS4-CAG-CYP2C19, which was digested with Ascl/AvrII, for the construction of HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 plasmid. Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/Ascl and ligated with the HS4-CAG-CYP3A4, which was digested with Ascl/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with Ascl/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/Ascl, for the construction of the PAC vector containing all four CYPs. Finally, HS4-CAG-POR plasmid was inserted to the PAC vector containing all four CYPs by the same technique mentioned above (S1A Fig). At all stages of the construction of the gene-loading PAC vector, PCR analysis was used to confirm that all target genes were loaded in sequence (S1B Fig).

Cell culture

A MAC6 vector was used to generate the 4CYPs-POR MAC. The structure of MAC6 contained a centromere from mouse chromosome 11, EGFP flanked by HS4 insulators, PGKneo, loxP-5'HPRT site, PGKpuro, and telomeres (S2 Fig) [27]. Hypoxanthine phosphoribosyl transferase (HPRT)-deficient Chinese hamster ovary (CHO; JCRB0218) hybrids containing only the MAC6 or the 4CYPs-POR MAC were maintained in Ham’s F-12 nutrient mixture (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 600 μg/mL G418. HepG2 cells (HB-8065, ATCC, USA) were maintained in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum, non-essential amino acids (Wako), pyruvate (Wako), and penicillin-streptomycin (Wako).

Microcell-mediated chromosome transfer (MMCT)

Measles virus envelope protein-mediated-MMCT (MV-MMCT) was performed as described previously [22, 28]. CHO cells containing 4CYPs-POR MAC and expressing MV-H and MV-F proteins were used as donor microcell hybrids. We transiently expressed the MV-H and MV-F in CHO cells with the 4CYPs-POR MAC. Next day, the cells were transferred into flasks, and after incubation overnight, micronuclei formation in CHO cells was induced by 72-hours treatment with 0.1 μg/mL colcemid. The cells were centrifuged with cytochalasin B to isolate microcells. Next, the collected microcells were cocultured with HepG2 cells for the fusion of micronuclei with the recipient cells. To select for HepG2 cells containing the 4CYPs-POR MAC, cells were cultured in media containing G418 (600 μg/mL). A few clones of HepG2 colonies appeared in each 100-mm dish. The distance between GFP-positive colonies on the culture dishes was sufficiently great to enable us to determine single colonies by visual inspection under a microscope. The colonies were dense, and there appeared to be no contamination with other colonies. The clones used for the tests in this study were derived from colonies not from the same culture dish but from different culture dishes. In each line, 4CYPs-POR MAC-
transferred HepG2 cells were characterized by PCR and fluorescence in-situ hybridization (FISH) analyses as follows.

**Fluorescence in situ hybridization (FISH)**
FISH analyses were performed using spreads of fixed chromosomes in either metaphase or interphase from each cell hybrid, a digoxigenin-labeled (Roche, Switzerland) mouse cot-1 DNA probe (Invitrogen), and a biotin-labeled 4CYPs-POR PAC probe. Chromosomal DNA was counterstained with DAPI. Images were captured using an AxioImagerZ2 fluorescence microscope (Carl Zeiss GmbH).

**Genomic polymerase chain reaction (PCR)**
Genomic DNA was extracted from cell lines using a genomic DNA extraction kit with DNase-free RNase (Gentra Systems, Minneapolis, USA). Primer sequences are listed in Table 1. Primers used for amplification of the 4CYPs-POR transgene spanned the intron and did not amplify any products in host genomic DNA.

**mRNA preparation and reverse transcription (RT)–quantitative PCR (qPCR) analysis**
mRNAs were extracted using the RNeasy Mini Kit (Qiagen, Germany), according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using an oligo-(dT) 20-mer primer and the SuperScript III reverse transcriptase (Invitrogen), according to the manufacturer’s instructions. Primer sequences are listed in Table 1. qPCR was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems) on an ABI Step One Plus device (Applied Biosystems). NAT1, a housekeeping gene, was used as control.

**Assessment of drug metabolism**
Measurement of the activity of all four CYPs was conducted using the P450-Glo™ assay (Promega, Japan), according to the manufacturer’s instructions. Briefly, cells were seeded in a 96-well plate at a density of 1×10⁴ cells/well. Twenty-four hours later, test compounds and the luminescent substrate included in the kit were added into the culture media. Following 1 hour of incubation, the detection reagent was added, and the luminescence generated by the metabolic substrate within the culture media was measured using an Infinite F500 plate reader (Wako). The inhibitor test conditions utilized in this study are listed in the results.

**Assessment of hepatotoxicity**
Hepatotoxicity of test compounds was determined by the ratio of surviving cells using the neutral red (NR) uptake assay (Kanto Chemical Co., Inc., Japan). Briefly, cells were seeded in a 96-well plate at a density of 1×10⁴ cells/well. After 24 hours, test compounds were added for an additional 48 hours. At the end of treatments, cells were washed with Dulbecco’s phosphate-buffered saline (Sigma-Aldrich), and NR-containing medium was added for an additional 3 hours. Following the removal of the NR medium, cells were washed, and NR was extracted. Optical density of wells was measured at 540 nm with a Sunrise Classic microplate reader (TECAN, Austria).

**Statistical analysis**
Curve fitting was performed using the SigmaPlot 13.0 statistical software (Systat Software, IL, USA). To determine compound concentrations to achieve 50% of maximum effective or
inhibitory response (IC_{50}, respectively), concentration-response data were fitted into a four-parameter sigmoidal (Hill) function. Data were presented as means ± S.D. Statistical analyses were carried out using unpaired Student’s t test. The level of statistical significance was set at P<0.05.

Results

Construction of the MAC vector containing 4CYPs and POR

CHO cells containing the empty MAC vector were transiently transfected with a Cre expression vector and the 4CYPs-POR PAC vector, as mentioned above (S2 Fig). The transfected cells were passaged the next day and were cultured with the selection medium containing HAT. Ultimately, a total of 40 HAT-resistant CHO cell clones carrying the MAC vector with the transgenes were obtained. Analysis by RT—qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. Genomic PCR analyses detected all transgenes in three clones (Fig 1A). We determined that all three clones exhibited high levels of expression for all four CYPs and POR (Fig 1B), as compared to the parental CHO cells that did not express any of the genes.

FISH analysis indicated that the MAC was independently maintained in these three CHO clonal cell lines (Fig 1C). Because we were also able to observe signals indicating the construct we introduced into the MAC, we were able to confirm that the desired MAC, designated as 4CYPs-POR MAC, was successfully constructed.
Transfer of the 4CYPs-POR MAC vector into HepG2 cells

MV-MMCT was performed to transfer 4CYPs-POR MAC from CHO cells into HepG2 cells, as described previously [28]. Eight GFP+/G418-resistant HepG2 clones were obtained. We randomly picked up three out of the eight GFP+/G418-resistant clones for following analyses. Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes (Fig 2B). Donor CHO cells were used as the positive control for genomic PCR, whereas the parental HepG2 cells were used as the negative control. FISH analysis of these three clones revealed that the 4CYPs-POR MAC was independently maintained in the HepG2 cells without integration or translocation into host chromosomes (Fig 2C). The HepG2 cells containing a single copy of 4CYPs-POR MAC were defined as transchromosomic-HepG2 (TC-HepG2) cell clones. Genes specifically expressed in liver cells [i.e., albumin (ALB) and tyrosine aminotransferase (TAT)] and a gene expressed in liver cancer/immature cells [i.e., α-fetoprotein (AFP)] were used as endogenous control genes. None of them was affected by either inter-clone competition. In contrast, RT—qPCR revealed that the expression levels of all five genes were higher in the TC-HepG2 cells than the parental HepG2 cells. Furthermore, the expression levels of these genes in the TC-HepG2 cells were similar to those in primary human hepatocytes, and there was minimal variation in transgene expression levels between the different clones (Fig 3A). Finally, the assessment of the metabolic activity of four CYPs indicated that all three clones were more active than the original HepG2 cells (Fig 3B) and that the CYP activity was either comparable or higher than those in primary human hepatocytes. In addition, we introduced the 4CYPs-POR MAC into HT1080 cells, which are human-derived non-hepatic cell lines. Consequently, although the gene expression increased, CYP activity was barely detectable. Variation between the TC-HepG2 clones, which was within the range of three folds, was minimal. Assessment of the inhibitory effect of clarithromycin [29] on CYP3A4 in three TC-HepG2 cells indicated that there was a concentration-dependent inhibitory effect on metabolic activity (Fig 3C). Overall, these results indicated that the 4CYPs-POR MAC was functional in the TC-HepG2 cells.
The TC-HepG2 cells were cultured until they reached 50 population doubling levels (PDLs), and the effect of drug selection (400 μg/mL G418) on the stability of the MAC and the 4CYPs-POR transgene expression was determined. First, stability of the 4CYPs-POR MAC during long-term culture conditions was assessed. The results indicated that the inserted genome was maintained in the presence and absence of the drug selection during long-term culturing (Fig 4A). Regarding endogenous gene expression (ALB, TAT, AFP), there was no change, regardless of long-term culture (Fig 4B). RT—qPCR revealed that there were no decreases in the expression level of the five transgenes on the MAC, indicating that stable gene expression was maintained during long-term culturing (Fig 4B). Even we cultured to 50 PDLs in the absence of selection drug G418, the expression levels for all genes were stable as well.

Because the loss of the 4CYPs-POR MAC from the TC-HepG2 cells was possible during long-term culturing, the retention rate of the MAC was determined using FISH analysis. The
results indicated that the MAC was stably maintained within the cells even after long-term culturing (Fig 4C).

Assessment of drug-drug interactions in TC-HepG2 cells

As the results thus far indicated that there was little variation among different TC-HepG2 clonal cell lines, the subsequent stability tests were performed using TC-HepG2 clone #1. Twenty compounds that are known to inhibit CYPs were used to calculate IC$_{50}$ values in TC-HepG2 cells, which were then compared to those in primary human hepatocytes. The results clearly demonstrated that all tested compounds exerted inhibitory effects in TC-HepG2 cells. Furthermore, the inhibitory effects of these compounds in TC-HepG2 cells were comparable to those reported in primary human hepatocytes (Table 2). Overall, these results suggested that the TC-HepG2 cells successfully replicated their CYP-inhibitory effects observed in human hepatocytes.

Fig 5 shows the results of the experiments assessing the irreversible inhibitory response of the TC-HepG2 cells to different compounds. The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol [30], ritonavir [31], mifepristone [32], erythromycin [33], clarithromycin [29], and roxithromycin [29]; CYP2C9 inhibitor tienilic acid [33]; CYP2C19 inhibitor ticlopidine [34]; and CYP2D6 inhibitor paroxetine [35]. Briefly, CYP inhibitors were added to the culture media at the same time as the metabolic substrate to test
direct inhibition (DI) or 1 hour prior to the addition of the metabolic substrate to test time-
dependent inhibition (TDI). The inhibitory effects of the compounds were higher in TC-
HepG2 cultures that were preincubated with the inhibitors than those that were incubated
with the inhibitor and the substrate simultaneously. These results were consistent with previ-
ous studies and suggested that TC-HepG2 cells could be used for the detection of TDI in vitro.

Fig 4. The 4CYPs-POR MAC stability and sustained transgene regulation in the TC-HepG2. TC-HepG2
cells were used for the following analyses before and after long-term culturing (50 PDLs) in the presence and
absence of selection with G418 (A-C). (A) Genomic PCR analysis of the 4CYPs-POR MAC in TC-HepG2
cells. (B) RT-qPCR analysis for expression of the transgenes and endogenous genes in TC-HepG2 cells. The
4CYPs-POR transgene expression levels at 50 PDLs are standardized to NAT1 expression, and the relative
each CYP and POR gene expression in each clone at 0 PDLs was used as control. Each column represents
the mean ± S.E. (n = 3). (C) FISH analyses for 4CYPs-POR MAC stability in TC-HepG2 cells (n = 25–30).
PDL, population doubling.

https://doi.org/10.1371/journal.pone.0187072.g004
We also determined whether three inhibitors (erythromycin, clarithromycin, and roxithromycin), which induced mechanism-based inhibition (MBI) in humans, exerted similar effects in TC-HepG2 cells [29]. Specifically, increasing concentrations of the inhibitors (0, 5, 10, 20, 40, or 100 μM) were added 10, 20, or 30 min prior to the addition of the luminescent CYP3A4 substrate, and the luminescence levels in culture media were used to determine metabolite levels. Fig 6A–6F shows percent changes in luminescence in cultures treated with the inhibitors compared to those in control cultures not treated with the inhibitors. All three inhibitors suppressed the generation of metabolites in a time- and concentration-dependent manner. Among the three compounds, all macrolide antibiotics, the inhibitory effect of roxithromycin is lower than those of erythromycin and clarithromycin in humans. Accordingly, the inhibitory effect of roxithromycin in TC-HepG2 cells was lower than those of the other two inhibitors. Further, because the CYP3A4 activity level in TC-HepG2 cells was higher than that in human hepatocytes (Fig 3), the rate of metabolic reduction by the inhibitors may be detected with high sensitivity. Fig 6G–6I show the plots to determine the rate of inactivation (k_{obs}) for the three inhibitors as depicted in Fig 6A–6F. Next, maximal inactivation (k_{inact}) and concentration at 50% k_{inact} (K_{app}) values were calculated as indicators of MBI, using the method by Taesotikul et al. (2011) [36]. The k_{inact} calculated based on the data presented in Fig 6G–6I showed that the inhibitory effect of roxithromycin was lower than those of the other two inhibitors (Table 3). In addition, for all compounds, K_{app}, indicating CYP reactivation, was lower in TC-HepG2 cells than in human hepatocytes. This finding suggested that TC-HepG2 cells could be used as a model to determine MBI with higher sensitivity than human hepatocytes.

### Table 2. Summary of *in vitro* inhibition data for CYP3A4, CYP2C9, CYP2C19, and CYP2D6 for 20 compounds. Values represent means ± S.D. of triplicate determinations.

| Target CYP | Drug      | IC50 (μM) | TC-HepG2 cells | Hepatocytes |
|------------|-----------|-----------|----------------|-------------|
| CYP3A4     | Ethinylestradiol | 0.97 ± 0.11 | 0.46 ± 0.05 |
|            | Gestodene   | 58.5 ± 4.6 | 7.4 ± 0.3     |
|            | Mifepristone | 11.9 ± 4.5 | 6.0 ± 0.4     |
|            | Erythromycin | 5.7 ± 1.7  | 3.4 ± 0.2     |
|            | Clarithromycin | 5.9 ± 0.3  | 5.0 ± 0.2     |
|            | Roxithromycin | 7.9 ± 0.2  | 9.9 ± 0.2     |
|            | Diltiazem    | 9.1 ± 4.1  | 7.4 ± 0.4     |
|            | Ritonavir    | 0.74 ± 0.03| 1.0 ± 0.6     |
|            | Ketoconazole | 0.067 ± 0.010 | 0.047 ± 0.005 |
|            | Fluconazole  | 1.98 ± 0.34| 2.0 ± 0.2     |
|            | Cimetidine   | 41 ± 19    | 7.1 ± 0.3     |
|            | Rifampicin   | 131.4 ± 21.6| 78 ± 12       |
| CYP2C9     | Ticlopidine  | 0.37 ± 0.03| 0.35 ± 0.04   |
|            | Omeprazole   | 4.4 ± 0.5  | 8.4 ± 0.7     |
| CYP2C19    | Tienilic acid | 5.7 ± 1.7  | 0.55 ± 0.02   |
|            | Fluvoxamine  | 0.0042 ± 0.0007 | 0.0030 ± 0.0004 |
| CYP2D6     | Paroxetine  | 10.9 ± 4.5 | 6.8 ± 0.7     |
|            | Fluoxetine   | 0.056 ± 0.049 | 0.044 ± 0.006 |
|            | Quinidine    | 0.0089 ± 0.0003 | 0.089 ± 0.003 |
|            | Terbinafine  | 0.0021 ± 0.0002 | 0.0099 ± 0.0002 |

CYP; cytochrome P450

https://doi.org/10.1371/journal.pone.0187072.t002
Assessment of metabolic toxicity in TC-HepG2 cells

Next, we determined whether TC-HepG2 cells could be used to determine the metabolic toxicity of two compounds, aflatoxin B1 and sterigmatocystin. Both aflatoxin B1 and sterigmatocystin convert to active metabolites via CYP3A4 and exert hepatotoxicity through DNA damage [37, 38]. As shown in Fig 7, the cell survival rates were significantly lower in TC-HepG2 cells treated with either compound than in parental HepG2 cells under the same conditions. These results indicated that the TC-HepG2 cells could be used to assess not only hepatic metabolism but also hepatotoxicity of compounds associated with CYP-mediated metabolism.

Discussion

Generation of highly reliable data requires the development of a highly reproducible model that produces few interfacility differences [3–5]. Several studies previously reported gene transfer into HepG2 cells using various methods [14–19]. However, due to the issues inherent to vector-based methods, even cells established at one research may not be reproducible by conventional gene transfer technologies at other facilities, which severely limits their utility in drug discovery research. Therefore, in the current study, we established HepG2 cell line using MAC vectors [20–23] to assess drug metabolism and toxicity as a reliable and reproducible system. Our findings indicated that one copy of the MAC with the 4CYPs-POR genes was transferred to parental HepG2 cells, which were detected alongside the host chromosomes. We also found that these transgenes were stably retained within the cells even after long-term culturing.

Fig 5. Relationship between relative CYP activity level and inhibitor concentration. Relative CYP activity was determined as the ratio of CYP-specific luminescence in the presence of the specific inhibitors to that in the absence of the same inhibitor. Open circles represent the values in cultures treated with the inhibitor and the CYP-specific luminescent substrate simultaneously [direct inhibition (DI)], and closed circles represent the values in cultures pretreated with the inhibitor for 60 min before the addition of the luminescent substrate (time-dependent inhibition). Values represent means ± S.D. (n = 4). *P < 0.05 vs each DI group.

https://doi.org/10.1371/journal.pone.0187072.g005
In addition, because the copy numbers of the transferred genes could be controlled, there was minimal clonal variation (Fig 3). Moreover, transgene expression was maintained over the long-term culture conditions, and CYP activities derived from the transgenes were either comparable or higher than those detected in human hepatocytes. Altogether, these results indicated that the TC-HepG2 cell lines were exceptionally stable and exhibited a high degree of metabolic activity.

![Fig 6. Inhibitory effects of macrolides on CYP-mediated metabolism in TC-HepG2 cells.](https://doi.org/10.1371/journal.pone.0187072.g006)

Table 3. Determination of $k_{\text{inact}}$ and $K_{\text{app}}$ for metabolism-dependent inhibition of CYP3A4 by macrolides. Apparent inactivation rates ($k_{\text{obs}}$) were estimated graphically from the slope of the plot for the natural log of enzyme activity remaining after preincubation against preincubation time and were corrected for any loss of activity in the absence of the inhibitor. $k_{\text{inact}}$ and $K_{\text{app}}$ values were obtained from a double reciprocal plot of $k_{\text{obs}}$ against inhibitor concentration. Data represent means ± S.D. of triplicate determinations.

|                   | TC-HepG2 cells | Hepatocytes |
|-------------------|----------------|-------------|
|                   | $k_{\text{inact}}$  | $K_{\text{app}}$ | $k_{\text{inact}}$ | $K_{\text{app}}$ |
| Erythromycin      | 2.29 ± 0.14     | 1.53 ± 0.96  | 2.43 ± 0.24  | 25.4 ± 5.6   |
| Clarithromycin    | 2.56 ± 0.08     | 3.76 ± 0.42  | 2.52 ± 0.29  | 16.0 ± 4.3   |
| Roxithromycin     | 1.55 ± 0.06     | 4.60 ± 0.60  | 0.58 ± 0.08  | 13.1 ± 4.7   |

TC; Transchromosomic

https://doi.org/10.1371/journal.pone.0187072.t003
POR is a flavin enzyme that supplies electrons necessary for enzymatic reactions catalyzed by CYPs. When no genes were introduced, HepG2 cells exhibited low expression of POR and CYP. To complement the lack of expression, we incorporated the POR gene. In addition, we introduced the 4CYPs-POR MAC into HT1080 cells, which are human-derived non-hepatic cell lines. Consequently, although the gene expression increased, CYP activity was barely detectable. These results suggest that the introduction of other factors, in addition to POR as a coenzyme, is required to create substitutable hepatic cells from human non-hepatic cells for testing CYP metabolism.

One major reason for the dropout of candidate compounds during development the removal of novel drugs from the market after launch [39–45] is drug-drug interactions (DDIs) caused by CYP inhibition [46–48]. To avoid DDIs, pharmaceutical companies implement CYP inhibition studies starting with the initial drug discovery stage. CYP inhibition patterns are categorized as either DI or TDI [49]. Most of the DI actions of compounds are reversible; therefore, inhibitory effects of the administered drug itself diminish as it is removed from the body through metabolism and excretion. While, potential mechanisms for TDI include the formation of a tight-binding, quasiirreversible inhibitory metabolite complex or the inactivation of CYPs by covalent adduct formation, which is retained even after the administered drug itself is eliminated from the body. As a result, in clinical settings, TDI often leads to far more serious adverse effects than DI. Therefore, in early stages of drug discovery, clear distinctions between DI and TDI are necessary for accurate assessment of candidate compounds. In the current study, we performed inhibition studies in TC-HepG2 cells using existing medical compounds. The result demonstrating that the extremely high IC50 values were highly correlated than those determined in human hepatocytes suggested that the TC-HepG2 cells were a viable alternative to human hepatocytes. All four CYP molecular species could replicate the TDI reported by previous studies using human hepatocytes. In order to assess these DDIs in detail, we calculated the k_inact and K_i,app values as well. The results indicated that the inhibitory effects of these compounds were highly dependent on the inhibitor concentration and that the drug metabolic reactivity was higher than that in human hepatocytes. These findings suggested that the TC-HepG2 cell model was useful in DDI assessment.

One mechanism of drug hepatotoxicity is metabolic activation. The report by a National Institutes of Health group in the United States, which reported on reactive metabolites of the antipyretic analgesic acetaminophen in the 1970s, is the first to highlight the significance of the
assessment of toxic metabolic intermediates of drugs [50]. Other examples of pharmaceutical-induced hepatotoxicity caused by metabolic activation include the diabetes drug troglitazone and the prostate cancer drug flutamide [51–55]. All these compounds are metabolically activated by CYPs, which is the main enzyme responsible for drug metabolism [17, 56]. The toxicity of these compounds was impossible to detect at the nonclinical trial stage, and their toxicity profiles were only discovered after their launch. Particularly, troglitazone caused death early after its launch, leading to its discontinuation [57]. Hepatotoxicity can result from the metabolic activation of the causative compound in some cases; therefore, to investigate whether the TC-HepG2 cell model was able to detect hepatotoxicity, we tested the cell toxicity profiles of two compounds whose toxicities were shown to result from their metabolism by CYPs. The aflatoxin B1 forms DNA adduct as a result of metabolic activation induced mainly by CYP3A4 [37]. This results in the DNA replication inhibition, which manifests as cytotoxicity. Sterigmatocystin is a biosynthesized intermediate of aflatoxin B1 and was shown to exert toxicity via the same mechanism as aflatoxin B1 [38]. The results presented in the current study indicated that both compounds led to a concentration-dependent decrease in the survival of TC-HepG2 cells (Fig 7), whereas neither compound was toxic at the same concentrations in parental HepG2 cells lacking CYPs. These results suggest that the TC-HepG2 cells could be utilized to assess cytotoxicity of active metabolites of compounds.

The MAC system was successfully used to establish the TC-HepG2 cell model. In addition to those mentioned above, the other merit of the MAC system is the flexibility with which genetic modifications can be introduced at any stage of the construction. To this end, multiple gene integrations into the MAC can be achieved via a multiple integrase system [58] or via simultaneous/sequential integration systems [59]. These genetic modification techniques theoretically allow an infinite number of genetic modifications to be introduced to MACs, which are then transferred into various host cells and continuous refinements. Thus, although only four CYPs were introduced in the current study, if needed, this approach allows for the addition of other genes, which can significantly decrease both the cost and time required for research. This stable gene transfer method allows not only the transfer of genes used in the current study but also the retransfer of several other pharmacokinetics-related genes. Overall, this streamlined method permits the establishment of cell-based models which can exhibit the nearly identical drug metabolism and pharmacokinetics profiles of human cells that can be refined further. In summary, the TC-HepG2 cells generated and characterized in the current study can provide a highly versatile model for use during the early stages of drug discovery, which require a high degree of processing capacity and reliability.

Supporting information

S1 Fig. PAC construction of the 4CYPs-POR. (A) Map of the 4CYPs-POR cassette constructed in a PAC vector. The expression cassette comprised cDNAs for CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, each under the control of a CAG promoter and flanked with HS4 insulators. The 4CYPs-POR cassette was followed by exons 3–9 of human HPRT gene and a loxP site. (B) Confirmation of the PAC construction by PCR.

S2 Fig. Image of 4CYPs-POR PAC loading to the MAC6 in CHO cells.

S3 Fig. Expression of endogenous control genes. Each column represents the mean ± S.E. (n = 3). Each gene expression in HepG2 cells as a control revealed 100%.
Acknowledgments

We thank Dr. H. Kugoh, Dr. M. Hiratsuka, and Dr. Y. Nakajima at Tottori University for critical discussions. This work was supported, in part, by Grants-in-Aid from the Japan Society for the Promotion of Science (26893153 to DS, 16K18942 to DS) and the Regional Innovation Strategy Support Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Y.K. and M.O.). There was no additional external funding received for this study. This research was partly performed at Tottori Bio Frontier managed by Tottori prefecture.

Author Contributions

Conceptualization: Satoshi Abe, Mitsuo Oshimura, Yasuhiro Kazuki.

Data curation: Daisuke Satoh, Satoru Iwado, Satoshi Abe, Shinobu Wakuri, Mitsuo Oshimura, Yasuhiro Kazuki.

Formal analysis: Daisuke Satoh, Satoru Iwado, Satoshi Abe, Shinobu Wakuri, Mitsuo Oshimura, Yasuhiro Kazuki.

Funding acquisition: Daisuke Satoh, Mitsuo Oshimura, Yasuhiro Kazuki.

Investigation: Daisuke Satoh.

Methodology: Daisuke Satoh, Satoru Iwado, Shinobu Wakuri, Mitsuo Oshimura.

Project administration: Daisuke Satoh, Shinobu Wakuri.

Resources: Kanako Kazuki.

Writing – original draft: Daisuke Satoh.

Writing – review & editing: Daisuke Satoh, Satoshi Abe, Shinobu Wakuri, Mitsuo Oshimura, Yasuhiro Kazuki.

References

1. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Hengstler JG. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013; 87(8):1315–1530. https://doi.org/10.1007/s00204-013-1078-5 PMID: 23974980

2. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci. 2001; 13(4):343–368 PMID: 11408150

3. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab. 2003; 4(4):292–312. PMID: 12871046

4. Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood). 2014; 239(9):1180–1191.

5. Kawai H, Kudo N, Kawashima Y, Mitsumoto A. Efficacy of urine bile acid as a non-invasive indicator of liver damage in rats. J Toxicol Sci. 2008; 34(1):27–38. PMID: 19182433

6. Knasmüller S, Mersch-Sundermann V, Kevekordes S, Darroudi F, Huber WW, Hoelzl C, et al. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology. 2004 20; 198(1–3):315–328. PMID: 15138058

7. Saito J, Okamura A, Takeuchi K, Hanioka K, Okada A, Ohata T. High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. Toxicol In Vitro. 2016; 33:63–70. https://doi.org/10.1016/j.tiv.2016.02.019 PMID: 26921665

8. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003; 31(8):1035–1042. PMID: 12867492
9. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001; 15(3):245–256. PMID: 11377097

10. Xu JJ, Diaz D, O’Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact. 2004; 150(1):115–128. PMID: 15522265

11. Zahno A, Brecht K, Morand R, Maseneni S, Török M, Lindinger PW, Krähenbühl S. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol. 2011; 81(3):432–441. https://doi.org/10.1016/j.bcp.2010.11.002 PMID: 21070748

12. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003; 42(2):153–178. PMID: 12537515

13. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienza FA. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012; 28(2):69–87. https://doi.org/10.1007/s10565-011-9208-4 PMID: 22258563

14. Gómez-Lechón MJ, Tolosa L, Donato MT. Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing. Expert Opin Drug Metab Toxicol. 2017; 13(2):137–148. https://doi.org/10.1080/17425255.2017.1238459 PMID: 21070748

15. Iwamura A, Fukami T, Hosomi H, Nakajima M, Yokoi T. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos. 2011; 39(5):838–846. https://doi.org/10.1124/dmd.110.037259 PMID: 21321060

16. Hosomi H, Fukami T, Iwamura A, Nakajima M, Yokoi T. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos. 2011; 39(8):1388–1395. https://doi.org/10.1124/dmd.110.037077 PMID: 21540358

17. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter RD, Monsouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology. 2005; 216(2–3):154–167. PMID: 16169652

18. Huang L, Zou S, Deng J, Dai T, Jiang J, Jia Y, Dai R, Xie S. Development of an optimized cytotoxicity assay system for CYP3A4-mediated metabolic activation via modified piggyBac transposition. Toxicol In Vitro. 2016; 32:132–137. https://doi.org/10.1016/j.tiv.2015.12.008 PMID: 26706816

19. Xuan J, Chen S, Ning B, Tolleson WH, Guo L. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact. 2016; 255:63–73. https://doi.org/10.1016/j.cbi.2015.10.009 PMID: 26477383

20. Kazuki Y, Oshimura M. Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther. 2011; 19(9):1591–1601. https://doi.org/10.1038/mt.2011.136 PMID: 21750534

21. Oshimura M, Uno N, Kazuki Y, Katoh M, Inoue T. A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challenges. Chromosome Res. 2015; 23:111–133. https://doi.org/10.1007/s10577-014-9459-z PMID: 25657031

22. Katoh M, Ayabe F, Norikane S, Okada T, Masumoto H, Horike SI et al. Construction of a novel human artificial chromosome vector for gene delivery. Biochem Biophys Res Commun. 2004; 321:280–290. PMID: 15358173

23. Kazuki Y, Hoshiya H, Takiguchi M, Abe S, Iida Y, Osaki M, et al. Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther. 2011; 18: 384–393. https://doi.org/10.1038/gt.2010.147 PMID: 21085194

24. Hiratsuka M, Uno N, Ueda K, Kurosaki H, Imaoka N, Kazuki K, et al. Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One. 2011; 6(10):e25961. https://doi.org/10.1371/journal.pone.0025961 PMID: 21998730

25. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270:414–423. PMID: 8035341

26. Gomes AM, Winter S, Klein K, Turpeinen M, Schaefler E, Schwab M, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009; 10(4):579–599. https://doi.org/10.2217/pgs.09.7 PMID: 19374516

27. Takiguchi M, Kazuki Y, Hiramatsu K, Abe S, Iida Y, Takehara S, et al. A novel and stable mouse artificial chromosome vector. ACS Synth Biol. 2012; 3:903–914. https://doi.org/10.1021/sb3000723 PMID: 23654286
28. Katoh M, Kazuki Y, Kazuki K, Kajitani N, Takiguchi M, Nakayama Y, et al. Exploitation of the interaction of measles virus fusogenic envelope proteins with the surface receptor CD46 on human cells for microcell-mediated chromosome transfer. BMC Biotechnol. 2010; 10(1):37.

29. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006; 316(1):336–348. PMID: 16192315

30. Robertson SM, Luo X, Dubey N, Li C, Chavan AB, Gilmartin GS, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015; 55(1):56–62. https://doi.org/10.1002/jcph.377 PMID: 25103957

31. Mao J, Mohutsky MA, Harrelson JP, Goldstein JL, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450. Biochemistry. 2001; 40(40):12112–12122. PMID: 11580286

32. He K, Woolf TF, Hollemberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther. 1999; 288(2):791–797. PMID: 9918590

33. Jean P, Lopez-Garcia P, Dansette P, Mansuy D, Goldstein JL. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur J Biochem. 1996; 241(3):797–804. PMID: 8944768

34. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003; 31(3):289–293. PMID: 12584155

35. Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet. 1995; 28(5):419–432. PMID: 7614779

36. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996; 335(4):290–291. PMID: 8657260

37. SoRelle R. Withdrawal of Posicor from market. Circulation. 1998; 98(9):831–832. PMID: 9738634

38. Kracyenbühl JC, Vozech S, Kondo-Oestreicher M, Dayer P. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol. 1999; 55(5):559–565. PMID: 10541773

39. Sica DA, Gehr TW. Rhombomyelosis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol. 2002; 11(1):48–55. PMID: 11773716

40. Bachmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother. 2005; 39(6):1064–1072. https://doi.org/10.1345/aph.1E508 PMID: 15886285

41. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005; 4(4):825–833. https://doi.org/10.1038/nrd1851 PMID: 16224454

42. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008; 9(4):310–322. PMID: 18473749

43. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol. 2000; 40:133–157. https://doi.org/10.1146/annurev.pharmtox.40.1.133 PMID: 10836130
50. Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol. 2016; 4(2):131–142. https://doi.org/10.14218/JCTH.2015.00052 PMID: 27350943

51. Nassar AE, Lopez-Anaya A. Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discov Devel. 2004; 7(1):126–136. PMID: 14982156

52. Wolfgang GH, Johnson DE. Web resources for drug toxicity. Toxicology. 2002; 173(1–2):67–74. PMID: 11955684

53. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005; 4(6):489–499. https://doi.org/10.1038/nrd1750 PMID: 15931258

54. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003; 349(5):474–485. https://doi.org/10.1056/NEJMra021844 PMID: 12890847

55. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev. 2004; 36(2):301–312. https://doi.org/10.1081/DMR-120034148 PMID: 15237856

56. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis. 2007; 11(3):459–475. https://doi.org/10.1016/j.cld.2007.06.001 PMID: 17723915

57. Yamamoto Y, Yamazaki H, Ikeda T, Watanabe T, Iwabuchi H, Nakajima M, et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos. 2002; 30(2):155–160. PMID: 11792684

58. Yamaguchi S, Kazuki Y, Nakayama Y, Nanba E, Oshima M, Ohbayashi T. A method for producing transgenic cells using a multi-integrase system on a human artificial chromosome vector. PLoS One. 2011; 6(2):e17267. https://doi.org/10.1371/journal.pone.0017267 PMID: 21390305

59. Suzuki T, Kazuki Y, Oshima M, Hara T. A novel system for simultaneous or sequential integration of multiple gene-loading vectors into a defined site of a human artificial chromosome. PLoS One. 2014; 9(10):e110404. https://doi.org/10.1371/journal.pone.0110404 PMID: 25305219